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Introduction
Acute lymphoblastic leukemia (ALL) and chronic
lymphocytic leukemia (CLL) are the most common
types of leukemia in children and in adults, respective-
ly. ALL can be cured in more than 80%, but some
patients suffer from refractory or recurrent disease and
cannot be cured with conventional chemotherapy [18].
Therefore new treatment approaches, like effective
and safe immunotherapy, are needed. The use of can-
cer vaccines based on dendritic cells (DC) presenting
tumor antigens can be a promising tool. Dendritic cells
play a pivotal role in the immune response as well as
in the induction of specific antitumor reaction. They
take up antigens, present them to T cells as peptides
bound to both MHC class I and II products and control
the type of T cell response [15]. Dendritic cells can be
generated from peripheral blood monocytes with the
use of various stimuli (preferably GM-CSF, TNF-α and
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Abstract: The use of cancer vaccines based on dendritic cells (DC) presenting tumor antigens can be a promising tool in
the treatment of leukemia. The functional characteristics of leukemia derived DC is still to be elucidated. CD40 promotes
survival, proliferation and differentiation of normal B cells. CD40 triggering was used to enhance the poor antigen-pre-
senting capacity of leukemic B-cells. Since it is still unclear whether CD40 ligation drives neoplastic B-cells to apoptosis
or not, we assessed the mRNA expression of FLICE, FAS, FADD and TRADD - important components of apoptosis machin-
ery, using real-time PCR in acute lymphoblastic leukemia cells before and after CD40 and IL-4 stimulation. ALL cells stim-
ulated with CD40L/IL-4 expressed dendritic cell phenotype at mRNA and protein levels (upregulation of main costimula-
tory and adhesion molecules noted in real-time RT PCR and flow cytometry); they also expressed higher amounts of mRNA
for FLICE, TRADD and FADD after CD40L/IL-4 stimulation. However differences statistically significant comparing cells
cultured with CD40L/IL-4 and medium alone regarded only FLICE. Concluding, we showed upregulation of important ele-
ments of apoptosis at mRNA level in ALL cells after CD40 ligation.
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IL-4) and media (RPMI 1640 supplemented with 2%
human serum albumin, 2% TCH, X-VIVO 15 or
Panserin 501) [24]. An interesting approach, intensively
examined in the last few years involves the differentia-
tion of leukemic cells into DC which could combine
both APC function and expression of tumor antigens
[16]. Our findings and data reported by other authors
seem to demonstrate that such approach is feasible, but
the functional characteristics of leukemia derived DC is
still to be elucidated [3,14]. Immunotherapy could be a
clinical option in a group of patients with high risk of
recurrence of the disease. CD40, a member of TNF fam-
ily, promotes survival, proliferation and differentiation
of normal B cells. The CD40-CD40 ligand (CD40L)
system is of pivotal importance in the immune response
via interactions between T cells and antigen-presenting
cells. CD40 triggering was used to enhance the poor
antigen-presenting capacity of leukemic B-cells. Even
in heavily pretreated patients, including children with
ALL and AML, autologous tumor vaccine expressing
CD40L and IL-2 resulted in clinical and laboratory
response [21]. Intravenous infusion of leukemic cells
after CD40 ligation in adult patients with B-CLL result-
ed not only in a reduction in leukemic cell counts and
lymph node size but also caused an increase in T-cell
counts [26].
Modulation of signal transduction pathways also
represents a promising tool for treating hematologic
malignancies. Disregulation of cell death mechanism
may contribute to oncogenesis. Apoptosis is a type of
programmed cell death involved in many biological
processess and many diseases such as cancer, AIDS
and autoimmunity, are associated with either too much
or too little apoptosis. It also plays a special role in the
immune system [13]. Apoptosis forms the basic mech-
anism for the action of chemotherapeutic agents on
cancer cells. FAS (CD95) is the best-known death
receptor. CD95 ligation results in the enrollment of
Fas-associated death domain protein (FADD) and pro-
caspase-8 (FLICE), forming together death-inducing
signaling complex (DISC) [5,13]. The formation of
DISC leads to the release of caspase-8, cleavage of
caspase-3 or amplification of the apoptotic signal via
mitochondria and finally to apoptosis. FADD and cas-
pase 8 are also essential for the DISC formation with
TRAIL-R1 and R2 and play a central role in signaling
via death receptors. Caspases are the proteases neces-
sary for execution of apoptosis and could also be a
potential target for the new cancer therapies. Inhibition
of caspases prevents cell death but there also exists a
caspase-independent mechanism of apoptosis. 
Some authors have found a relationship between
the expression of molecules involved in apoptosis and
survival in patients with hematologic malignancies;
the expression of FLIP (Fas-associated death domain-
like interleukin 1 beta-converting enzyme-like
inhibitory protein) was a positive prognostic factor in
the treatment of elderly AML patients [12]. In another
study, low Fas expression was a predictor for poor out-
come in ALL [23]. Lack of the Ki67 antigen expres-
sion, one of the most sensitive markers of prolifera-
tion, may represent an unfavourable prognosis in chil-
dren with AML [17]. Survivin, an inhibitor of apopto-
sis could also serve as a prognostic factor in non-small
cell lung cancer - its overexpression was correlated
with shorter survival [10].
Lately the treatment with CD40L and IL-10 result-
ed in reconstitution of IgA secretion in IgA-deficient
humans. It has been indicated that this mechanism is
associated with protection of CD20+ B cells from
apoptosis (e.g. increase in IAP-2 inhibitor of apoptosis
expression) [9]. 
Since it is still unclear whether CD40 ligation
drives neoplastic B-cells to apoptosis or not, we decid-
ed to assess the mRNA expression of FLICE, FAS,
FADD and TRADD - important elements of apoptosis
machinery, using real-time PCR in acute lymphoblas-
tic leukemia cells before and after CD40L and IL-4
stimulation.
Materials and methods
Patients. Children with B-cell precursor acute lymphoblastic
leukemia (BCP-ALL) were prospectively enrolled into the study
(N=25, 13 boys=52% and 12 girls=48%, aged 2-17 years, mean
6.84 ± 4.6). The patients were treated in departments of pediatric
hematology and oncology in Bia³ystok, Warszawa, Bydgoszcz,
Chorzów and Zabrze according to the protocol recommended by
the Polish Pediatric Leukemia/Lymphoma Study Group, ALL IC-
BFM 2002 (September 2005 to January 2006). Peripheral blood
samples or bone marrow were taken at the time of diagnosis,
before any treatment. Bone marrow was obtained when more than
80% of blast infiltration was present, peripheral blood - when the
leukocyte count was more than 10 × 109/l and blasts accounted for
over 90% of mononuclear cells in differential white blood cell
count. In the study group the white blood count range was 2.5-36
× 109/l, mean 10.47 ± 9.08, the percentage of peripheral blasts was
1-92%, mean 42.4 ± 27.4. The study was approved by the institu-
tional review board and informed consent was obtained from
patients and their parents.
Cells and culture. Mononuclear cells from bone marrow or
peripheral blood samples were obtained via density-gradient cen-
trifugation, frozen immediately in fetal calf serum (FCS, Sigma)
containing 10% dimethyl sulphoxide (DMSO, Sigma) and stored in
liquid nitrogen. Thawed ALL cells (>80% vital cells) were resus-
pended in medium (RMPI-1640/FBS 90%/10%), cultured in 24-well
flat-bottom plates at a concentration of 1 × 105/ml and stimulated (or
not) with CD40L (3 μg/ml, a kind gift of Immunex/Amgen, USA)
and IL-4 (80 ng/ml, Sigma). The cells were incubated in a total vol-
ume of 1ml/well at 37°C in 5% CO2 for 96 hours. After the culture,
ALL cells were gently removed and used for flow cytometry and
mRNA isolation. The trypan blue (Sigma) exclusion assay was used
to study cell viability. All assessed samples had at least 80% viable
cells before and after the culture.
Real-time quantitative PCR. The mRNA was isolated from
mononuclear cells using Dynabeads mRNA Direct Micro Kit
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(Dynal) according to the producer's instructions. The first strand of
cDNA was synthesized using random hexamers as primer and
High Capacity cDNA Archive Kit by Applied Biosystems. Six dif-
ferent costimulatory/adhesion molecules at mRNA level (CD1a,
CD40, CD54, CD80, CD83, CD86) and four - involved in apop-
tosis (FAS, FLICE, TRADD, FADD) were determined by real-
time PCR technique with the TaqMan chemistry using ready-to-
use Low Density Arrays for Gene Expression by Applied Biosys-
tems. It contained target-specific primers and probe and TaqMan
Universal Master Mix, containing AmpErase uracil-N-glycosy-
lase (UNG) to prevent the re-amplification of carryover PCR
products. The PCR amplification and fluorescence data collec-
tion were performed with ABI PRISM 7900HT Sequence Detec-
tion System (Applied Biosystems). To normalize the amount of
expressed mRNAs, the internal housekeping gene GAPDH was
used and each complementary DNA (cDNA) product was tested
in quadruplicates for each of ten molecule mRNA and GAPDH
mRNA. To calculate our data we used Comparative Ct method
for relative quantification (Ct method) which describes the
change in expression of the target gene in a test sample relative
to a calibrator sample and provides accurate comparison between
the initial level of template in each sample. As a calibrator sam-
ple we used Total Raji RNA by Applied Biosystems which was
processed in the same way as the test samples. Data were ana-
lyzed with Sequence Detector System (SDS) software version 2.1
(Applied Biosystems).
Flow cytometry. Immunophenotyping was performed as previ-
ously described [14]. Briefly, cultured cells were incubated for 20
min with monoclonal antibodies, then samples were washed twice
with PBS and analyzed with Beckman Cytomics FC 500 MPL. The
following fluorescein isothiocyanate (FITC)-, phycoerythrin (PE)-
or peridinin chlorophyll protein (PerCP)-conjugated monoclonal
antibodies (and isotype controls) were used: CD1a, CD10, CD11c,
CD19, CD40, CD45, CD54, CD80, CD83, CD86, CD123, HLA
class I, HLA-DR (all purchased from Beckton Dickinson, USA).
All gates were set using appropriate isotype control antibodies.
Percentages of positive cells were calculated. A minimum of 104
events was acquired for each analysis. Results are expressed as
percentage of positive cells (%) among stained cells. The purity of
leukemic cells was always higher than 90% (determined by flow
cytometry).
Statistical analysis. Statistical analysis was performed using
Access '97 and Statistica 6.0 for Windows. The results were not
normally distributed and are expressed as median and 25th-75th
percentile. Significance levels were calculated according to the
nonparametric Wilcoxon test (comparison between results
obtained before and after stimulation with CD40L and IL-4 and
between groups stimulated with cytokines and medium alone). In
all analyses, p value less than 0.05 was considered significant.
Results
ALL cells stimulated with CD40L and IL-4
express phenotype of dendritic cells at mRNA
and protein level
After the culture with CD40L and IL-4, a statistically
significant rise in all assessed cell populations was
noted, i.e. in HLA class I and II, CD1a+, CD11c+,
CD40+, CD83+, CD54+, CD80+, CD86+ and CD123+
cells. For example, leukemic cells with CD80+ and
CD86+ coexpression increased from 5% and 14% to
16% and 30%, respectively (p=0.0001, p=0.0005). An
increase in was also observed in mRNA levels for
CD40, CD54 and CD80 after CD40L and IL-4 stimu-
lation (data not shown, differences were statistically
significant). There was also a tendency for the higher
median mRNA levels for CD83 and CD86 after the
culture with CD40L than before the culture (statisti-
cally insignificant). Results obtained from real-time
PCR and flow cytometry show that CD40 ligation
induced up-regulation or de novo expression of critical
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Table 1. Results obtained from real-time PCR for molecules involved in apoptosis (mean mRNA expression of FAS, FLICE, FADD and
TRADD).
costimulatory and adhesion molecules on leukemic
cells. 
ALL cells express higher amounts of mRNA
for FLICE, TRADD and FADD after CD40L
and IL-4 stimulation
Results concerning the molecules involved in apopto-
sis, obtained from real-time PCR are presented in
Table 1 and Fig. 1. Median expression of mRNA for
FLICE and TRADD was higher after CD40 stimula-
tion than before the culture. However only in FLICE
the expression after culture with CD40L/IL-4 was sig-
nificantly higher than after the culture with medium
alone (p=0.04). This tendency also referred to FADD
molecule, but was not statistically significant (p=0.07). 
Discussion
To test the influence of CD40 ligation on apoptosis in
leukemic cells we examined ALL blast cells for
expression of mRNA for FAS, FADD, FLICE and
TRADD before and after CD40L and IL-4 stimulation.
As expected, flow cytometry and real-time PCR show-
ing upregulation of critical costimulatory and adhesion
molecules confirmed that ALL blasts can be converted
into dendritic-like cells. After CD40 stimulation, an
increase in mRNA levels for FLICE, FADD and
TRADD was noted - these results could indicate acti-
vation of apoptosis in leukemic cells. From the clinical
point of view, activation of apoptosis in leukemic cells
would be a useful effect in cancer immunotherapy. 
The majority of experiments on apoptosis in
leukemic cells concern CLL in adults, characterized by
a slow accumulation rate and availability of tumor
cells in peripheral blood and thus represents an ideal
target for autologous vaccination immunotherapy
since. Results obtained to date are discrepant. Several
studies (from one laboratory center - Genoa, Italy)
have shown that CLL cells are initially resistant to CD-
95 mediated apoptosis. This resistance is probably due
to high expression of X-linked inhibitor of apoptosis
protein (XIAP) [11], one of the inhibitors of apoptosis
proteins (IAPs). Novel XIAP inhibitor, 1540-14,
enhances CD95-mediated apoptosis of CLL cells. This
effect is mediated by activation of caspases-8 (FLICE)
and -3 and could be useful in immunotherapy [11].
According to Farahani et al. it is possible that the anti-
apoptotic effect of CD40 ligation on CLL cells is also
mediated by VEGF, a well known cell survival pro-
moter [7]. Our study was performed after 96 hours of
culture. After such time CLL cells are sensitive to
18 W. £uczyñski et al. 
Fig. 1. mRNA expression for FAS, FLICE, FADD and TRADD in ALL cells before and after the culture with CD40L and IL-4.
CD95-mediated apoptosis and this effect is associated
with upregulation of proapoptotic protein - Bid B-cell
leukemia 2 homology 3 (BH3) interacting with
domain death agonist [11]. According to other authors,
this sensitization is mediated through an increase in
FADD and DAP3 expression [2]. In another study,
genes involved in apoptosis, e.g. CASP8 and FADD-
like apoptosis regulator (FLICE), were upregulated in
B-CLL cells after CD40 activation - those results are
similar to our observations in ALL [8]. Most recent
studies has shown that CD40 ligation sensitizes CLL
cells to apoptosis through the activation of p73 (a p53-
related transcription factor regulated by c-Abl kinase).
CD40 activation also induced CD95 and Bid (BH3-
interacting-domain death agonist) expression in
leukemic cells [6]. In contrast to our observations, de
Totero et al. noted that in B-CLL, FAS mRNA was up-
regulated after CD40 triggering but expression of
other DISC molecules, i.e. FLICE, FADD and
TRADD did not change in resting and activated cells
[5]. They concluded that DISC molecules were not
involved in this phenomenon. Despite CD95 upmodu-
lation shown in their study, B-CLL cells were still
resistant to CD95-mediated apoptosis. Another
approach was presented by Romano et al. [20]: T cells
from patients with B-CLL, preactivated with phorbol
12-myristate 13-acetate (PMA) and ionomycin, led to
higher susceptibility of leukemic cells to apoptosis via
CD95 upregulation.
Interesting results concerning apoptosis of normal
DC (not derived from neoplasmatic cells) in patients
with breast cancer were obtained by Pinzon-Charry et
al. [19]: supernatants from cancer lines induced
apoptosis of DC but this effect could be prevented by
ex vivo conditioning of DC with CD40L and/or IL-
12. Additionally, DC expressing TRAIL (inducer of
apoptosis) were effective for protection against
leukemia relapse. TRAIL-transduced DC showed
cytotoxicity through the induction of apoptosis in
both leukemic cells and alloreactive T cells in graft-
versus-host disease (GvHD) [22]. However, anti-
CD40 monoclonal antibody led to reduced function
of DC in generating an effective T-cell response. This
was due to apoptosis via activation of FADD and
caspase-8. Authors of that report emphasize this
immunosuppressive activity [4].
In infant ALL cells, the low expression of FAS tran-
scripts and low level of FAS protein is considered to be
the main mechanism responsible for the resistance of
these cells to apoptosis [27]. In another type of
leukemia - AML - CD40 engagement rescued
leukemic blasts from apoptosis. This effect was shown
by reduced expression of APO2.7 and annexin-V bind-
ing, and additionally by upregulation of bcl-x (L) pro-
tein [1]. CD40 ligation also blocked apoptosis and
induced multidrug resistance in non-Hodgkin's lym-
phoma cells through caspase independent and depend-
ent pathways [25]. 
Concluding, we showed upregulation of important
elements of apoptosis at mRNA level in ALL cells after
CD40L and IL-4 stimulation. Understanding of apopto-
sis machinery in leukemic cells may provide new ther-
apeutic potentials. The findings seem to support thera-
peutic exploitation of CD40 stimulation in ALL,
despite its unclear influence on apoptotic profile of
leukemic cells. We hope that our observations may
have future implications for the therapy of ALL in chil-
dren, e.g. in sensitizing leukemic cells to chemotherapy. 
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